Shire (SHPG) Institutional Ownership : 24.63% (As of Apr. 26, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Shire Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Shire's institutional ownership is 24.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Shire's Insider Ownership is 0.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Shire's Float Percentage Of Total Shares Outstanding is 0.00%.

Shire Institutional Ownership Historical Data

The historical data trend for Shire's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Institutional Ownership Chart

Shire Historical Data

The historical data trend for Shire can be seen below:

	2018-03-31	2018-04-30	2018-05-31	2018-06-30	2018-07-31	2018-08-31	2018-09-30	2018-10-31	2018-11-30	2018-12-31
Institutional Ownership	25.95	26.23	25.99	24.83	23.99	24.01	25.60	25.38	25.22	24.63

Shire Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085